Leap Therapeutics Inc (NASDAQ:LPTX) — Market Cap & Net Worth
Market Cap & Net Worth: Leap Therapeutics Inc (LPTX)
Leap Therapeutics Inc (NASDAQ:LPTX) has a market capitalization of $116.14 Million ($116.14 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18627 globally and #4117 in its home market, demonstrating a 391.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Leap Therapeutics Inc's stock price $2.05 by its total outstanding shares 56651840 (56.65 Million). Analyse cash efficiency ratio of Leap Therapeutics Inc to see how efficiently the company converts income to cash.
Leap Therapeutics Inc Market Cap History: 2017 to 2025
Leap Therapeutics Inc's market capitalization history from 2017 to 2025. Data shows change from $3.54 Billion to $116.14 Million (-33.92% CAGR).
Index Memberships
Leap Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #526 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1813 of 3165 |
Weight: Leap Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Leap Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Leap Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
679.82x
Leap Therapeutics Inc's market cap is 679.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $634.50 Million | $375.00K | -$32.90 Million | 1692.00x | N/A |
| 2020 | $1.27 Billion | $10.05 Million | -$3.39 Million | 126.79x | N/A |
| 2021 | $1.84 Billion | $1.50 Million | -$40.59 Million | 1223.68x | N/A |
| 2022 | $254.93 Million | $375.00K | -$54.60 Million | 679.82x | N/A |
Competitor Companies of LPTX by Market Capitalization
Companies near Leap Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Leap Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Leap Therapeutics Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, Leap Therapeutics Inc's market cap moved from $3.54 Billion to $ 116.14 Million, with a yearly change of -33.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $116.14 Million | -28.70% |
| 2024 | $162.87 Million | -30.64% |
| 2023 | $234.82 Million | -7.89% |
| 2022 | $254.93 Million | -86.11% |
| 2021 | $1.84 Billion | +44.00% |
| 2020 | $1.27 Billion | +100.89% |
| 2019 | $634.50 Million | -44.00% |
| 2018 | $1.13 Billion | -67.95% |
| 2017 | $3.54 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Leap Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.14 Million USD |
| MoneyControl | $116.14 Million USD |
| MarketWatch | $116.14 Million USD |
| marketcap.company | $116.14 Million USD |
| Reuters | $116.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more